Latest Period
Q4 2025
Security Snapshot
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) Institutional Ownership
CUSIP: 22978P106
13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026
Institutions Reporting
48
Shares (Excl. Options)
21,788,519
Price
$0.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- CUE on Nasdaq
- Shares outstanding
- 43,411,663
- Price per share
- $0.47
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 21,788,519
- Total reported value
- $6,659,692
- % of total 13F portfolios
- 0%
- Share change
- +3,729,510
- Value change
- +$1,059,340
- Number of holders
- 48
- Price from insider filings
- $0.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 22978P106.
- 48 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 48 to 9 between Q4 2025 and Q1 2026.
- Reported value moved from $6,659,692 to $122,644.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 48 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 22978P106?
CUSIP 22978P106 identifies CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22978P106:
Significant Owners of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Bleichroeder LP | 10% | 0% | $5,269,789 | 6,127,662 | 0% | Bleichroeder LP | 19 Mar 2025 | |
| STROME MARK E | 5% | $1,862,968 | 2,166,242 | Mark E. Strome | 14 Nov 2022 | |||
| Slate Path Capital LP | 1.4% | $790,199 | 918,836 | Slate Path Capital LP | 31 Dec 2024 |
As of 31 Dec 2025, 48 institutional investors reported holding 21,788,519 shares of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE). This represents 50% of the company’s total 43,411,663 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bleichroeder LP | 16% | 6,819,164 | 0% | 0.37% | $2,082,573 |
| GC Wealth Management RIA, LLC | 11% | 4,631,644 | +35% | 0.05% | $1,414,504 |
| VANGUARD GROUP INC | 6.9% | 3,014,034 | -0.83% | 0% | $919,280 |
| Lion Point Capital, LP | 5.1% | 2,202,854 | 3.5% | $672,752 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 803,291 | +0.32% | 0% | $245,361 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.6% | 704,297 | +15% | 0.01% | $215,092 |
| Robertson Stephens Wealth Management, LLC | 1.1% | 478,500 | 0% | 0% | $146,134 |
| BlackRock, Inc. | 1% | 449,162 | 0% | 0% | $137,174 |
| Texas Capital Bank Wealth Management Services Inc | 1% | 440,670 | +1231% | 0.01% | $134,580 |
| ANGELES WEALTH MANAGEMENT, LLC | 0.71% | 310,000 | +158% | 0.01% | $94,674 |
| ADVISORY RESEARCH INC | 0.59% | 257,225 | 0% | 0.01% | $78,557 |
| STIFEL FINANCIAL CORP | 0.57% | 246,556 | +25% | 0% | $75,298 |
| RENAISSANCE TECHNOLOGIES LLC | 0.55% | 238,354 | +5% | 0% | $72,793 |
| BANK OF AMERICA CORP /DE/ | 0.48% | 207,569 | -36% | 0% | $63,309 |
| STATE STREET CORP | 0.41% | 179,353 | -5.5% | 0% | $54,774 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.39% | 168,829 | +1.4% | 0% | $51,561 |
| NORTHERN TRUST CORP | 0.23% | 100,957 | -0% | 0% | $30,832 |
| Chicago Partners Investment Group LLC | 0.2% | 85,937 | 0% | 0% | $32,656 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 0.18% | 79,500 | 0% | 0% | $24,280 |
| JANE STREET GROUP, LLC | 0.16% | 69,793 | 0% | $21,315 | |
| UBS Group AG | 0.11% | 46,848 | -76% | 0% | $14,288 |
| LPL Financial LLC | 0.11% | 46,390 | 0% | 0% | $14,167 |
| Sigma Planning Corp | 0.09% | 41,050 | -23% | 0% | $12,537 |
| HRT FINANCIAL LP | 0.05% | 20,863 | 0% | $6,000 | |
| NewEdge Advisors, LLC | 0.05% | 20,000 | 0% | 0% | $6,108 |
Institutional Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 531,713 | $122,644 | +$131 | $0.23 | 9 |
| 2025 Q4 | 21,788,519 | $6,659,692 | +$1,059,340 | $0.31 | 48 |
| 2025 Q3 | 18,058,960 | $12,982,249 | +$519,709 | $0.72 | 52 |
| 2025 Q2 | 17,351,508 | $11,856,298 | +$3,983,649 | $0.68 | 46 |
| 2025 Q1 | 11,402,706 | $10,374,424 | -$452,161 | $0.91 | 49 |
| 2024 Q4 | 11,759,494 | $12,816,995 | -$1,528,241 | $1.09 | 55 |
| 2024 Q3 | 13,910,388 | $10,533,734 | -$288,922 | $0.76 | 50 |
| 2024 Q2 | 13,807,875 | $17,121,019 | -$3,730,383 | $1.24 | 72 |
| 2024 Q1 | 16,387,055 | $30,971,606 | +$2,715,659 | $1.89 | 74 |
| 2023 Q4 | 14,886,167 | $39,304,464 | +$2,537,424 | $2.64 | 80 |
| 2023 Q3 | 14,014,675 | $32,148,839 | -$634,604 | $2.30 | 75 |
| 2023 Q2 | 13,849,849 | $50,545,862 | +$6,687,288 | $3.65 | 77 |
| 2023 Q1 | 12,055,434 | $43,037,472 | -$2,540,576 | $3.57 | 62 |
| 2022 Q4 | 12,761,302 | $36,370,518 | +$155,907 | $2.85 | 60 |
| 2022 Q3 | 12,797,287 | $28,665,093 | -$2,995,285 | $2.23 | 61 |
| 2022 Q2 | 14,083,808 | $35,042,763 | -$10,988,434 | $2.49 | 68 |
| 2022 Q1 | 17,812,661 | $87,010,965 | +$4,491,451 | $4.88 | 97 |
| 2021 Q4 | 16,533,577 | $187,228,947 | -$11,058,319 | $11.31 | 88 |
| 2021 Q3 | 16,892,813 | $245,597,815 | -$23,967,610 | $14.57 | 87 |
| 2021 Q2 | 18,582,224 | $216,368,968 | -$2,774,327 | $11.65 | 89 |
| 2021 Q1 | 18,817,560 | $229,653,033 | -$6,452,286 | $12.20 | 88 |
| 2020 Q4 | 19,314,982 | $241,658,115 | -$3,019,434 | $12.51 | 94 |
| 2020 Q3 | 19,517,235 | $293,948,076 | +$49,950,366 | $15.05 | 90 |
| 2020 Q2 | 16,042,165 | $393,156,090 | +$84,955,728 | $24.51 | 99 |
| 2020 Q1 | 13,033,369 | $184,956,981 | +$36,613,314 | $14.19 | 72 |
| 2019 Q4 | 10,554,208 | $167,568,706 | +$63,118,277 | $15.88 | 60 |
| 2019 Q3 | 6,080,606 | $51,262,809 | +$13,288,944 | $8.43 | 44 |
| 2019 Q2 | 4,501,012 | $40,453,546 | +$9,997,120 | $8.99 | 36 |
| 2019 Q1 | 3,453,175 | $26,693,413 | +$1,831,681 | $7.73 | 37 |
| 2018 Q4 | 3,229,210 | $15,171,419 | -$2,037,779 | $4.70 | 34 |
| 2018 Q3 | 3,579,962 | $32,396,140 | +$3,237,621 | $9.05 | 36 |
| 2018 Q2 | 3,148,586 | $37,344,175 | +$15,445,827 | $11.86 | 37 |
| 2018 Q1 | 1,844,607 | $25,915,405 | +$25,915,405 | $14.05 | 28 |